Literature DB >> 12651620

Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism.

Jian Chen1, Songji Zhao, Kunihiro Nakada, Yuji Kuge, Nagara Tamaki, Futoshi Okada, Jingxin Wang, Masanobu Shindo, Fumihiro Higashino, Kohji Takeda, Masahiro Asaka, Hiroyuki Katoh, Toshio Sugiyama, Masuo Hosokawa, Masanobu Kobayashi.   

Abstract

In the tumor cells exposed to hypoxia, hypoxia-inducible factor-1 (HIF-1)-mediated adaptation responses such as angiogenesis and anaerobic metabolism are induced for their survival. We have recently reported that the constitutive expression of HIF-1 alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and glucose deprivation. We then established dominant-negative HIF-1 alpha (dnHIF-1 alpha) transfectants and examined their susceptibility to apoptosis and growth inhibition induced by hypoxia and glucose deprivation in vitro and their tumorigenicity in SCID mice. We further examined the expressions of aldolase A and Glut-1 in vitro and Glut-1 expression and glucose uptake in the tumor tissues and microvessel counts in the tumor tissues. As a result, dnHIF-1 alpha rendered the pancreatic cancer cells sensitive to apoptosis and growth inhibition induced by hypoxia and glucose deprivation. Also it abrogated the enhanced expression of Glut-1 and aldolase A mRNAs under hypoxia and reduced the expression of Glut-1 and the glucose uptake in the tumor tissues and consequently in vivo tumorigenicity. We found no significant difference in the microvessel counts among the tumor tissues. From these results, we suggest that the disruption of the HIF-1 pathway might be effective in the treatment of pancreatic cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651620      PMCID: PMC1851236          DOI: 10.1016/s0002-9440(10)63924-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Suppression of tumor growth through disruption of hypoxia-inducible transcription.

Authors:  A L Kung; S Wang; J M Klco; W G Kaelin; D M Livingston
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

2.  Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors.

Authors:  Y Tsuzuki; D Fukumura; B Oosthuyse; C Koike; P Carmeliet; R K Jain
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

3.  Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin.

Authors:  S Choi; M Kobayashi; J Wang; H Habelhah; F Okada; J Hamada; T Moriuchi; Y Totsuka; M Hosokawa
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor.

Authors:  K A Vincent; K G Shyu; Y Luo; M Magner; R A Tio; C Jiang; M A Goldberg; G Y Akita; R J Gregory; J M Isner
Journal:  Circulation       Date:  2000-10-31       Impact factor: 29.690

5.  Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.

Authors:  D Delbeke; D M Rose; W C Chapman; C W Pinson; J K Wright; R D Beauchamp; Y Shyr; S D Leach
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

Review 6.  Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours.

Authors:  I Ak; M P Stokkel; E K Pauwels
Journal:  J Cancer Res Clin Oncol       Date:  2000-10       Impact factor: 4.553

Review 7.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.

Authors:  M Höckel; P Vaupel
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

8.  Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.

Authors:  H E Ryan; M Poloni; W McNulty; D Elson; M Gassmann; J M Arbeit; R S Johnson
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

Review 9.  Angiogenesis: how a tumor adapts to hypoxia.

Authors:  D E Richard; E Berra; J Pouysségur
Journal:  Biochem Biophys Res Commun       Date:  1999-12-29       Impact factor: 3.575

10.  Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.

Authors:  P Carmeliet; Y Dor; J M Herbert; D Fukumura; K Brusselmans; M Dewerchin; M Neeman; F Bono; R Abramovitch; P Maxwell; C J Koch; P Ratcliffe; L Moons; R K Jain; D Collen; E Keshert; E Keshet
Journal:  Nature       Date:  1998-07-30       Impact factor: 49.962

View more
  52 in total

1.  MiR-199a suppresses the hypoxia-induced proliferation of non-small cell lung cancer cells through targeting HIF1α.

Authors:  Gang Ding; Gang Huang; He-dai Liu; Hong-xiang Liang; Yu-feng Ni; Zhao-heng Ding; Guo-ying Ni; Hong-wei Hua
Journal:  Mol Cell Biochem       Date:  2013-12       Impact factor: 3.396

2.  HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met.

Authors:  Galia Tsarfaty; Gideon Y Stein; Sharon Moshitch-Moshkovitz; Dafna W Kaufman; Brain Cao; James H Resau; George F Vande Woude; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors.

Authors:  Ian F Robey; Anthony D Lien; Sarah J Welsh; Brenda K Baggett; Robert J Gillies
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

4.  Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

Authors:  Bénédicte F Jordan; Matthew Runquist; Natarajan Raghunand; Amanda Baker; Ryan Williams; Lynn Kirkpatrick; Garth Powis; Robert J Gillies
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 5.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

6.  Optical glucose analogs of aminolevulinic acid for fluorescence-guided tumor resection and photodynamic therapy.

Authors:  Eduardo H Moriyama; Weiguo Cao; Tracy W Liu; Han Lin Wang; Peter D Kim; Juan Chen; Gang Zheng; Brian C Wilson
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

7.  Cancer Stem Cells under Hypoxia as a Chemoresistance Factor in Breast and Brain.

Authors:  Spencer W Crowder; Daniel A Balikov; Yu-Shik Hwang; Hak-Joon Sung
Journal:  Curr Pathobiol Rep       Date:  2014-03

8.  Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.

Authors:  Ayush Sharma; Thomas C Smyrk; Michael J Levy; Mark A Topazian; Suresh T Chari
Journal:  Gastroenterology       Date:  2018-04-30       Impact factor: 22.682

Review 9.  Restoration of mitochondria function as a target for cancer therapy.

Authors:  Tariq A Bhat; Sandeep Kumar; Ajay K Chaudhary; Neelu Yadav; Dhyan Chandra
Journal:  Drug Discov Today       Date:  2015-03-09       Impact factor: 7.851

10.  Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction.

Authors:  Kai Sun; Nils Halberg; Mahmood Khan; Ulysses J Magalang; Philipp E Scherer
Journal:  Mol Cell Biol       Date:  2012-12-17       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.